Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric F Johnson

Showing results (91-100 of 122) with videos related to

Pageof 13
Sort By:
Cancer Research|May 3, 2008
ABT-263: a potent and orally bioavailable Bcl-2 family inhibitorChristin Tse, Alexander R Shoemaker, Jessica Adickes, et al.
Bioorganic & Medicinal Chemistry Letters|April 29, 2006
Discovery and SAR of oxindole-pyridine-based protein kinase B/Akt inhibitors for treating cancersGui-Dong Zhu, Viraj B Gandhi, Jianchun Gong, et al.
Journal of Medicinal Chemistry|October 22, 2009
Discovery of 3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-ones as potent, highly selective, and orally bioavailable inhibitors of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM) kinasesZhi-Fu Tao, Lisa A Hasvold, Joel D Leverson, et al.
Journal of Medicinal Chemistry|January 16, 2009
Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancerThomas D Penning, Gui-Dong Zhu, Viraj B Gandhi, et al.
Molecular Cancer Research : MCR|October 17, 2008
Potentiation of temozolomide cytotoxicity by poly(ADP)ribose polymerase inhibitor ABT-888 requires a conversion of single-stranded DNA damages to double-stranded DNA breaksXuesong Liu, Yan Shi, Ran Guan, et al.
Lung Cancer (Amsterdam, Netherlands)|July 26, 2021
Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancerDavid E Kozono, Thomas E Stinchcombe, Joseph K Salama, et al.
Bioorganic & Medicinal Chemistry Letters|May 9, 2006
Identification of a novel 3,5-disubstituted pyridine as a potent, selective, and orally active inhibitor of Akt1 kinaseSheela A Thomas, Tongmei Li, Keith W Woods, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2011
Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitorXuesong Liu, Yan Shi, David X Maag, et al.
Journal of Medicinal Chemistry|November 6, 2009
Synthesis and evaluation of a new generation of orally efficacious benzimidazole-based poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors as anticancer agentsYunsong Tong, Jennifer J Bouska, Paul A Ellis, et al.
Bioorganic & Medicinal Chemistry Letters|April 11, 2006
Isoquinoline-pyridine-based protein kinase B/Akt antagonists: SAR and in vivo antitumor activityGui-Dong Zhu, Jianchun Gong, Akiyo Claiborne, et al.
Pageof 13

Showing results (91-100 of 122) with videos related to

Sort By:
Pageof 13
Cancer Research|May 3, 2008
ABT-263: a potent and orally bioavailable Bcl-2 family inhibitorChristin Tse, Alexander R Shoemaker, Jessica Adickes, et al.
Bioorganic & Medicinal Chemistry Letters|April 29, 2006
Discovery and SAR of oxindole-pyridine-based protein kinase B/Akt inhibitors for treating cancersGui-Dong Zhu, Viraj B Gandhi, Jianchun Gong, et al.
Journal of Medicinal Chemistry|October 22, 2009
Discovery of 3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-ones as potent, highly selective, and orally bioavailable inhibitors of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM) kinasesZhi-Fu Tao, Lisa A Hasvold, Joel D Leverson, et al.
Journal of Medicinal Chemistry|January 16, 2009
Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancerThomas D Penning, Gui-Dong Zhu, Viraj B Gandhi, et al.
Molecular Cancer Research : MCR|October 17, 2008
Potentiation of temozolomide cytotoxicity by poly(ADP)ribose polymerase inhibitor ABT-888 requires a conversion of single-stranded DNA damages to double-stranded DNA breaksXuesong Liu, Yan Shi, Ran Guan, et al.
Lung Cancer (Amsterdam, Netherlands)|July 26, 2021
Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancerDavid E Kozono, Thomas E Stinchcombe, Joseph K Salama, et al.
Bioorganic & Medicinal Chemistry Letters|May 9, 2006
Identification of a novel 3,5-disubstituted pyridine as a potent, selective, and orally active inhibitor of Akt1 kinaseSheela A Thomas, Tongmei Li, Keith W Woods, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2011
Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitorXuesong Liu, Yan Shi, David X Maag, et al.
Journal of Medicinal Chemistry|November 6, 2009
Synthesis and evaluation of a new generation of orally efficacious benzimidazole-based poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors as anticancer agentsYunsong Tong, Jennifer J Bouska, Paul A Ellis, et al.
Bioorganic & Medicinal Chemistry Letters|April 11, 2006
Isoquinoline-pyridine-based protein kinase B/Akt antagonists: SAR and in vivo antitumor activityGui-Dong Zhu, Jianchun Gong, Akiyo Claiborne, et al.
Pageof 13